Cardiovascular outcomes associated with SGLT2 vs DPP4 inhibitors in type 2 diabetic patients with and without established cardiovascular diseases: a propensity score-matched study
The combined treatment with glucagon like peptide-1 analogues and sodium-glucose co-transporter 2 causes a greater improvement of arterial stiffness than each treatment alone in type 2 diabetes .